Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
This guide is part of our pillar: Dementia Medications Compared Donepezil Rivastigmine Memantine.
Related guide: Cognitive Tests for Dementia — our comprehensive resource on this topic.
Cholinesterase inhibitors are the foundation drug class for Alzheimer’s disease. The category includes donepezil, rivastigmine, and galantamine. Here is what every family should understand about cholinesterase inhibitors before starting one.
Understanding cholinesterase inhibitors helps families ask better questions and make calmer decisions. The detail below covers what doctors usually skip when explaining cholinesterase inhibitors.
What They Do
Block the enzyme that breaks down acetylcholine, leaving more of this memory-relevant neurotransmitter in synapses.
Who Benefits Most
Mild to moderate Alzheimer’s patients. Modest benefit also documented in Lewy body and Parkinson’s disease dementia.
Expected Benefit Size
A 1 to 2 point MMSE improvement, modest functional benefit, and 6 to 12 months of stability before decline resumes.
Common Side Effects
Nausea, diarrhea, weight loss, vivid dreams, muscle cramps, bradycardia. Most resolve or improve over 4 to 8 weeks.
When They Are Stopped
No measurable benefit at 6 months, intolerable side effects, advanced dementia where benefit is unclear, or transition to comfort care.
Frequently Asked Questions
Do cholinesterase inhibitors help vascular dementia?
Some benefit in mixed Alzheimer’s/vascular cases. Pure vascular dementia response is weaker.
Can two be combined?
No. Stacking two cholinesterase inhibitors causes severe side effects without added benefit.
For more, see Alzheimer’s Association.
